Call us + 65 6741-5520

Opening Hours Mon-Sat: 9:00 AM - 5:00 PM

Address 515 Dunman Rd, Singapore

CGAICC Health Genetic Testing for PTEN: What Patients Actually Need to Know

Genetic Testing for PTEN: What Patients Actually Need to Know

PTEN genetic testing looks for inherited or acquired changes in the PTEN gene, which helps regulate cell growth. For patients, the key point is that testing can clarify whether a personal or family history of certain cancers and other features may be part of PTEN hamartoma tumor syndrome (PHTS), guide cancer surveillance, and inform relatives about their own risks. A result is not a diagnosis of cancer: its meaning depends on the variant found, the reason for testing, and clinical evaluation. The National Cancer Institute and GeneReviews describe PHTS as an uncommon, inherited condition with important implications for breast, thyroid, kidney, endometrial, and colorectal cancer risk.

What PTEN genetic testing means for patients

PTEN genetic testing analyzes DNA for variants in the PTEN tumor-suppressor gene. The National Cancer Institute explains that pathogenic PTEN variants can cause PHTS, an umbrella term that includes Cowden syndrome and related clinical presentations. PTEN ordinarily helps restrain cell growth; when one copy carries a disease-causing inherited variant, cells may be more likely to grow abnormally and form benign growths or cancers.

PHTS is rare, and estimates vary with diagnostic criteria and how intensively people are assessed. GeneReviews cites an estimated birth incidence of about 1 in 200,000, while also noting that the condition may be underrecognized. The number is not an individual’s personal risk. For someone with a confirmed pathogenic variant, cancer risks are elevated and vary by organ, age, sex, family history, and the specific clinical context.

Testing is most useful when it answers a practical question: Does this person have a genetic explanation for their findings, should surveillance begin or change, and could relatives benefit from testing? Genetic counseling before and after testing helps patients understand those questions, the limits of results, possible effects on family members, and privacy or insurance considerations.

Who should consider PTEN genetic testing

Testing is generally considered when a person’s medical history, physical features, or family history raises suspicion for PHTS. GeneReviews and clinical criteria developed for Cowden syndrome describe combinations of characteristic cancers, benign growths, and physical findings that can prompt evaluation. No single feature proves that someone has a PTEN variant; a genetics professional considers the whole pattern.

Personal or family history that raises suspicion

A clinician may refer someone for genetics assessment after an early or unusual cancer, multiple primary cancers, or a family pattern involving cancers associated with PHTS. Relevant cancers include breast, non-medullary thyroid, renal cell, and endometrial cancer, as well as colorectal cancer and melanoma in some clinical assessments. A family history becomes more informative when several relatives have related findings, cancers occur at younger ages, or the same person has multiple characteristic features.

PHTS can also involve noncancerous findings, such as hamartomatous polyps, certain skin or mouth lesions, and an enlarged head circumference (macrocephaly). Developmental differences, including autism spectrum disorder or developmental delay, may also be part of the presentation. These findings are common in the general population, so their presence alone does not establish PHTS.

Testing children and young people

Testing a child may be appropriate when results could change care during childhood, such as when a clinician is evaluating developmental or physical features or considering age-appropriate thyroid surveillance. The decision should be individualized with a genetics team. Predictive testing solely for adult-onset risks is commonly approached differently from testing that could guide medical care while the child is growing up.

How PTEN testing works and what the results mean

A genetics professional usually begins with a three-generation family history and a review of personal medical records and examination findings. The laboratory then analyzes a blood or saliva sample. Testing may include PTEN sequencing, which looks for small changes in the gene, and deletion/duplication analysis, which looks for missing or extra sections. A multigene panel may be used when several inherited conditions could explain the findings.

Pathogenic or likely pathogenic result

A pathogenic or likely pathogenic result means the laboratory considers the identified variant disease-causing or very likely disease-causing. In someone whose clinical findings fit, it can confirm a molecular diagnosis of PHTS and support risk-based surveillance. It may also allow targeted testing for the specific family variant in relatives. A positive result does not mean cancer is present or certain to develop.

Negative result

A negative result means the test did not identify a reportable disease-causing variant in the genes and regions analyzed. It does not always rule out PHTS or inherited risk. The explanation may be that the person’s findings have another cause, that the family history is due to a different gene, or that current testing did not detect the relevant change. If clinical suspicion remains strong, clinicians may recommend continued management based on personal and family history, review of the assay, or updated testing later.

Variant of uncertain significance

A variant of uncertain significance (VUS) is a DNA change for which available evidence is insufficient to determine whether it causes disease. A VUS is not the same as a positive result and should not, by itself, guide major medical decisions or predictive testing of relatives. Laboratories may reclassify variants as evidence accumulates, so patients can ask their genetics team how to receive updates.

What a PTEN diagnosis can mean for health care

A confirmed PHTS diagnosis can lead to a personalized plan for cancer surveillance and management of noncancerous manifestations. GeneReviews and the National Comprehensive Cancer Network (NCCN) recommend surveillance tailored to age, sex, personal history, family history, and current clinical guidance. Recommendations can change as evidence develops, so patients should confirm the current plan with clinicians familiar with hereditary cancer syndromes.

Cancer surveillance and risk reduction

Surveillance may include breast screening with MRI and mammography, thyroid evaluation, kidney imaging, and colonoscopy at intervals determined by current guidance and individual findings. Discussion of endometrial symptoms and risk is also important. The timing and frequency differ across guidelines and may depend on age and whether a person has already had cancer or undergone risk-reducing surgery.

Published estimates show why follow-up matters, but they should be interpreted cautiously. GeneReviews summarizes lifetime breast cancer risk in women with PHTS as approximately 85%, with average age at diagnosis around 38–46 years; lifetime thyroid cancer risk is estimated at about 35%. These are population estimates from available studies, not predictions for any one patient. Risks for other cancers are also elevated, but estimates vary across studies and families.

Surveillance is not a guarantee that cancer will be prevented or detected at a particular stage. It is a strategy to identify concerning changes earlier and support informed decisions. Patients should promptly report new symptoms and discuss the benefits, limitations, and potential harms of imaging or procedures with their care team.

Benign growths and other features

PHTS care is not limited to cancer screening. Some patients need assessment or treatment for skin and oral lesions, gastrointestinal polyps, thyroid nodules, or developmental and neurologic concerns. Care may involve genetics, primary care, dermatology, gastroenterology, endocrinology, oncology, and other specialists, coordinated around the patient’s needs.

Family testing, costs, and practical questions

Most PHTS caused by a germline PTEN variant is inherited in an autosomal dominant pattern. Each child of a person with a confirmed pathogenic variant has a 50% chance of inheriting it. This probability applies to each pregnancy independently; it does not mean a child will definitely develop cancer. Some cases arise from a new variant, so a person can have PHTS even without a known family history.

Once a familial pathogenic variant is identified, relatives can often have targeted testing for that exact change, which is generally more focused than repeating a broad panel. A relative who tests negative for the known family variant has not inherited that variant, although ordinary population risks and any separate family-history risks still apply.

Before testing, ask the clinician or laboratory about the test’s scope, turnaround time, out-of-pocket cost, coverage, and whether the result could affect medical or life-planning decisions. In the United States, the Genetic Information Nondiscrimination Act (GINA) generally protects against genetic discrimination in health insurance and employment, but it does not cover life, disability, or long-term-care insurance. Protections differ by jurisdiction, and patients may wish to understand local rules before testing.

A patient-focused checklist

  • Ask why PTEN testing is being recommended and whether a single-gene test or multigene panel is more appropriate.
  • Share relevant medical records and a family history that includes cancer types and ages at diagnosis.
  • Ask how a positive, negative, or uncertain result would change care.
  • Discuss whether relatives may benefit from testing and how results can be shared with them.
  • Request a written surveillance plan and ask which clinician will coordinate follow-up.
  • Check how the laboratory handles reclassification of uncertain variants and how you can receive updates.

Conclusion: make PTEN testing useful, not frightening

PTEN genetic testing can explain a pattern of cancers or characteristic clinical findings, guide personalized surveillance, and help relatives make informed choices. Its value depends on interpreting the result correctly: pathogenic findings can confirm PHTS, negative findings do not always erase clinical risk, and a VUS is not a diagnosis. If you or a relative may have features associated with PHTS, ask a clinician for referral to a genetic counselor or genetics clinic. Bring your family history, request a clear explanation of possible results, and work with your care team to create a plan based on current guidance.

Sources: National Cancer Institute, “Cancer Genetics Risk Assessment and Counseling (PDQ®)–Health Professional Version,” https://www.cancer.gov/about-cancer/causes-prevention/genetics/risk-assessment-pdq; GeneReviews, “PTEN Hamartoma Tumor Syndrome,” https://www.ncbi.nlm.nih.gov/books/NBK1488/; National Comprehensive Cancer Network, “Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic,” https://www.nccn.org/guidelines/guidelines-detail?category=2&id=1503; U.S. Federal Trade Commission, “Genetic Information Nondiscrimination Act,” https://www.ftc.gov/legal-library/browse/statutes/genetic-information-nondiscrimination-act.

Leave a Reply

Your email address will not be published. Required fields are marked *